Candidate biomarkers for genetic and clinic opathological diagnosis of endometrial cancer

International Journal of Molecular Sciences

Volumn 14, Issue 6, 2013, Pages 12123-12137

  Banno, Kouji ^a   Nogami, Yuya ^a   Kisu, Iori ^a   Yanokura, Megumi ^a   Umene, Kiyoko ^a   Masuda, Kenta ^a   Kobayashi, Yusuke ^a   Yamagami, Wataru ^a   Susumu, Nobuyuki ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

CA125; CHFR; DNA hypermethylation; Endometrial cancer; K ras; Lynch syndrome; microRNA; Microsatellite instability; MSH6; PTEN

Indexed keywords

BETA CATENIN; BIOLOGICAL MARKER; K RAS PROTEIN; MICRORNA; MICRORNA 125A; MICRORNA 152; MICRORNA 15B; MICRORNA 17 5P; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 203; MICRORNA 205; MICRORNA 20A; MICRORNA 210; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 34B; MICRORNA 410; MICRORNA 424; MICRORNA 429; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MSH6; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANEUPLOIDY; BETA CATENIN GENE; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC ACCURACY; DNA METHYLATION; ENDOMETRIUM CANCER; EPIGENETICS; FAMILIAL CANCER; GENE MUTATION; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; MSH6 GENE; MUTATIONAL ANALYSIS; MUTATOR GENE; ONCOGENE K RAS; PHOSPHATIDYLINOSITOL 3 KINASE GENE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA GENE; PREDICTION; PTEN GENE; REVIEW; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY;

DNA METHYLATION; ENDOMETRIAL NEOPLASMS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879024352     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140612123     Document Type: Review

References (62)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
2. Ushijima, K. Current status of gynecologic cancer in Japan. J. Gynecol. Oncol. 2009, 20, 67-71.
3. Honda, T.; Urabe, R.; Kurita, T.; Kagami, S.; Kawagoe, T.; Toki, N.; Matsuura, Y.; Hachisuga, T. Trends in the demographic and clinicopathological characteristics in Japanese patients with endometrial cancer, 1990-2010. Int. J. Womens Health 2012, 4, 207-212.
4. Bokhman, J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983, 15, 10-17.
5. Deligdisch, L.; Cohen, C.J. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985, 56, 1452-1455.
6. Oehler, M.K.; Brand, A.; Wain, G.V. Molecular genetics and endometrial cancer. J. Br. Menopause Soc. 2003, 9, 27-31.
7. Bansal, N.; Yendluri, V.; Wenham, R.M. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009, 1, 8-13.
8. Gadducci, A.; Cosio, S.; Genazzani, A.R. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit. Rev. Oncol. Hematol. 2011, 80, 181-192.
9. Doll, A.; Abal, M.; Rigau, M.; Monge, M.; Gonzalez, M.; Demajo, S.; Colás, E.; Llauradó, M.; Alazzouzi, H.; Planagumá, J.; et al. Novel molecular profiles of endometrial cancer-new light through old windows. J. Steroid Biochem. Mol. Biol. 2008, 108, 221-229.
10. Esteller, M. Dormant hypermethylated tumour suppressor genes: Questions and answers. J. Pathol. 2005, 205, 172-180.
11. Bhalla, K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 2005, 23, 3971-3993.
12. Krusche, C.A.; Vloet, A.J.; Classen-Linke, I.; von Rango, U.; Beier, H.M.; Alfer, J. Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum. Reprod. 2007, 22, 2956-2966.
13. Weichert, W.; Denkert, C.; Noske, A.; Darb-Esfahani, S.; Dietel, M.; Kalloger, S.E.; Huntsam, D.G.; Köbel, M. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 2008, 10, 1021-1027.
14. Esteller, M.; Levine, R.; Baylin, S.B.; Ellenson, L.H.; Herman, J.G. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998, 17, 2413-2417.
15. Hecht, J.L.; Mutter, G.L. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 2006, 24, 4783-4791.
16. Bilbao, C.; Lara, P.C.; Ramírez, R.; Henríquez-Hernández, L.A.; Rodríguez, G.; Falcón, O.; León, L.; Perucho, M.; Díaz-Chico, B.N.; Díaz-Chico, J.C. Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76, 9-13.
17. Costello, J.F.; Plass, C. Methylation matters. J. Med. Genet. 2001, 38, 285-303.
18. Di Domenico, M.; Santoro, A.; Ricciardi, C.; Iaccarino, M.; Iaccarino, S.; Freda, M.; Feola, A.; Sanguedolce, F.; Losito, S.; Pasquali, D.; et al. Epigenetic fingerprint in endometrial carcinogenesis: The hypothesis of a uterine field concretization. Cancer Biol. Ther. 2011, 12, 447-457.
19. Scolnick, D.M.; Halazonetis, T.D. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 2000, 27, 430-435.
20. Chin, C.F.; Yeong, F.M. Safeguarding entry into mitosis the antephase checkpoint. Mol. Cell Biol. 2010, 30, 22-23.
21. Yanokura, M.; Banno, K.; Kawaguchi, M.; Hirao, N.; Hirasawa, A.; Susumu, N.; Tsukazaki, K.; Aoki, D. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol. Rep. 2007, 17, 41-48.
22. Bogen, K.T. Efficient tumorigenesis by mutation-induced failure to terminate microRNA-mediated adaptive hyperplasia. Med. Hypotheses 2013, 80, 83-90.
23. Zhi, F.; Wang, S.; Wang, R.; Xia, X.; Yang, Y. From small to big: microRNAs as new players in medulloblastomas. Tumor Biol. 2013, 34, 9-15.
24. Yanokura, M.; Banno, K.; Kobayashi, Y.; Kisu, I.; Ueki, A.; Ono, A.; Masuda, K.; Nomura, H.; Hirasawa, A.; Susumu, N.; et al. MicroRNA and endometrial cancer: Roles of small RNAs in human tumors and clinical applications. Oncol. Lett. 2010, 1, 935-940.
25. Devor, E.J.; Hovey, A.M.; Goodheart, M.J.; Ramachandran, S.; Leslie, K.K. MicroRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol. Rep. 2011, 26, 995-1002.
26. Snowdon, J.; Zhang, X.; Childs, T.; Tron, V.A.; Feilotter, H. The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One 2011, 6, e22828.
27. Lee, J.W.; Park, Y.A.; Choi, J.J.; Lee, Y.Y.; Kim, C.J.; Choi, C.; Kim, T.J.; Lee, N.W.; Kim, B.G.; Bae, D.S. The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol. 2011, 120, 56-62.
28. Torres, A.; Torres, K.; Pesci, A.; Ceccaroni, M.; Paszkowski, T.; Cassandrini, P.; Zamboni, G.; Maciejewski, R. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int. J. Cancer 2013, 132, 1633-1645.
29. Ramón, L.A.; Braza-Boïls, A.; Gilabert, J.; Chirivella, M.; España, F.; Estellés, A.; Gilabert-Estellés, J. MicroRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum. Reprod. 2012, 27, 3036-3045.
30. Hiroki, E.; Suzuki, F.; Akahira, J.; Nagase, S.; Ito, K.; Sugawara, J.; Miki, Y.; Suzuki, T.; Sasano, H.; Yaegashi, N. MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J. Cancer 2012, 131, E395-404.
31. Tsuruta, T.; Kozaki, K.; Uesugi, A.; Furuta, M.; Hirasawa, A.; Imoto, I.; Susumu, N.; Aoki, D.; Inazawa, J. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 2011, 71, 6450-6462.
32. Ketabi, Z.; Mosgaard, B.J.; Gerdes, A.M.; Ladelund, S.; Bernstein, I.T. Awareness of endometrial cancer risk and compliance with screening in hereditary nonpolyposis colorectal cancer. Obstet. Gynecol. 2012, 120, 1005-1012.
33. Kalady, M.F.; Lipman, J.; McGannon, E.; Church, J.M. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. Ann. Surg. 2012, 255, 1121-1125.
34. Banno, K.; Yanokura, M.; Kobayashi, Y.; Kawaguchi, M.; Nomura, H.; Hirasawa, A.; Susumu, N.; Aoki, D. Endometrial cancer as a familial tumor: Pathology and molecular carcinogenesis (review). Curr. Genomics 2009, 10, 127-132.
35. Banno, K.; Susumu, N.; Hirao, T.; Yanokura, M.; Hirasawa, A.; Aoki, D.; Udagawa, Y.; Sugano, K.; Nozawa, S. Two Japanese kindreds occurring endometrial cancer meeting new clinical criteria for hereditary non-polyposis colorectal cancer (HNPCC), Amsterdam Criteria II. J. Obstet. Gynaecol. Res. 2004, 30, 287-292.
36. Hirai, Y.; Banno, K.; Suzuki, M.; Ichikawa, Y.; Udagawa, Y.; Sugano, K.; Miki, Y. Molecular epidemiological and mutational analysis of DNA mismatch repair (MMR) genes in endometrial cancer patients with HNPCC-associated familial predisposition to cancer. Cancer Sci. 2008, 99, 1715-1719.
37. Banno, K.; Kisu, I.; Yanokura, M.; Tsuji, K.; Masuda, K.; Ueki, A.; Kobayashi, Y.; Yamagami, W.; Nomura, H.; Tominaga, E.; et al. Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome. Int. J. Oncol. 2012, 41, 793-797.
38. Gazzoli, I.; Loda, M.; Garber, J.; Syngal, S.; Kolodner, R.D. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 2002, 62, 3925-3928.
39. Ligtenberg, M.J.; Kuiper, R.P.; Chan, T.L.; Goossens, M.; Hebeda, K.M.; Voorendt, M.; Lee, T.Y.; Bodmer, D.; Hoenselaar, E.; Hendriks-Cornelissen, S.J.; et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat. Genet. 2009, 41, 12-17.
40. Nelen, M.R.; Kremer, H.; Konings, I.B.; Schoute, F.; van Essen, A.J.; Koch, R.; Woods, C.G.; Fryns, J.P.; Hamel, B.; Hoefsloot, L.H.; et al. Novel PTEN mutations in patients with Cowden disease: Absence of clear genotype-phenotype correlations. Eur. J. Hum. Genet. 1999, 7, 267-273.
41. Nelen, M.R.; Padberg, G.W.; Peeters, E.A.; Lin, A.Y.; van den Helm, B.; Frants, R.R.; Coulon, V.; Goldstein, A.M.; van Reen, M.M.; Easton, D.F.; et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat. Genet. 1996, 13, 114-116.
42. Liaw, D.; Marsh, D.J.; Li, J.; Dahia, P.L.; Wang, S.I.; Zheng, Z.; Bose, S.; Call, K.M.; Tsou, H.C.; Peacocke, M.; et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16, 64-67.
43. Salem, O.S.; Steck, W.D. Cowden's disease (multiple hamartoma and neoplasia syndrome). A case report and review of the English literature. J. Am. Acad. Dermatol. 1983, 8, 686-696.
44. Higuchi, M.; Onishi, K.; Kikuchi, C.; Gotoh, Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat. Cell. Biol. 2008, 10, 1356-1364.
45. Beggs, A.D.; Latchford, A.R.; Vasen, H.F.; Moslein, G.; Alonso, A.; Aretz, S.; Bertario, L.; Blanco, I.; Bulow, S.; Burn, J.; et al. Peutz-Jeghers syndrome: A systematic review and recommendations for management. Gut 2010, 59, 975-986.
46. Scully, R.E. Sex cord tumor with annular tubules a distinctive ovarian tumor of the Peutz-Jeghers syndrome. Cancer 1970, 25, 1107-1121.
47. Giardiello, F.M.; Brensinger, J.D.; Tersmette, A.C.; Goodman, S.N.; Petersen, G.M.; Booker, S.V.; Cruz-Correa, M.; Offerhaus, J.A. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000, 119, 1447-1453.
48. Banno, K.; Kisu, I.; Yanokura, M.; Tsuji, K.; Masuda, K.; Ueki, A.; Kobayashi, Y.; Yamagami, W.; Nomura, H.; Tominaga, E.; et al. Biomarkers in endometrial cancer: Possible clinical applications. Oncol. Lett. 2012, 3, 1175-1180.
49. Lee, E.J.; Kim, T.J.; Kim, D.S.; Choi, C.H.; Lee, J.W.; Lee, J.H.; Bae, D.S.; Kim, B.G. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: A clinicopathologic study of 131 cases and literature review. Gynecol. Oncol. 2010, 116, 533-538.
50. Risinger, J.I.; Hayes, K.; Maxwell, G.L.; Carney, M.E.; Dodge, R.K.; Barrett, J.C.; Berchuck, A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin. Cancer Res. 1998, 4, 3005-3010.
51. Mackay, H.J.; Gallinger, S.; Tsao, M.S.; McLachlin, C.M.; Tu, D.; Keiser, K.; Eisenhauer, E.A.; Oza, A.M. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur. J. Cancer 2010, 46, 1365-1373.
52. Saegusa, M.; Hashimura, M.; Yoshida, T.; Okayasu, I. Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br. J. Cancer 2001, 84, 209-217.
53. Mizuuchi, H.; Nasim, S.; Kudo, R.; Silverberg, S.G.; Greenhouse, S.; Garrett, C.T. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res. 1992, 52, 2777-2781.
54. Jo, H.; Kim, J.W.; Kang, G.H.; Park, N.H.; Song, Y.S.; Kang, S.B.; Lee, H.P. Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Oncol. Res. 2006, 16, 205-209.
55. Mizumoto, Y.; Kyo, S.; Mori, N.; Sakaguchi, J.; Ohno, S.; Maida, Y.; Hashimoto, M.; Takakura, M.; Inoue, M. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. Cancer Sci. 2007, 98, 652-658.
56. Chen, C.A.; Cheng, W.F.; Lee, C.N.; Wei, L.H.; Chu, J.S.; Hsieh, F.J.; Hsieh, C.Y. Cytosol vascular endothelial growth factor in endometrial carcinoma: Correlation with disease-free survival. Gynecol. Oncol. 2001, 80, 207-212.
57. Zaino, R.J.; Davis, A.T.; Ohlsson-Wilhelm, B.M.; Brunetto, V.L. DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int. J. Gynecol. Pathol. 1998, 17, 312-319.
58. Scambia, G.; Gadducci, A.; Panici, P.B.; Foti, E.; Ferdeghini, M.; Ferrandina, G.; Amoroso, M.; Castellani, C.; Facchini, V.; Mancuso, S. Combined use of CA 125 and CA 15-3 in patients with endometrial carcinoma. Gynecol. Oncol. 1994, 54, 292-297.
59. Sood, A.K.; Buller, R.E.; Burger, R.A.; Dawson, J.D.; Sorosky, J.I.; Berman, M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet. Gynecol. 1997, 90, 441-447.
60. Diefenbach, C.S.; Shah, Z.; Iasonos, A.; Barakat, R.R.; Levine, D.A.; Aghajanian, C.; Sabbatini, P.; Hensley, M.L.; Konner, J.; Tew, W.; et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol. Oncol. 2007, 104, 435-442.
61. Moore, R.G.; Brown, A.K.; Miller, M.C.; Badgwell, D.; Lu, Z.; Allard, W.J.; Granai, C.O.; Bast, R.C., Lu, K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 2008, 110, 196-201.
62. Mutz-Dehbalaie, I.; Egle, D.; Fessler, S.; Hubalek, M.; Fiegl, H.; Marth, C.; Widschwendter, A. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol. Oncol. 2012, 126, 186-191.